Dr. Caroline Chung is vice president and Chief Data & Analytics Office and Co-Director of the Institute for Data Science in Oncology at MD Anderson Cancer Center. She is a tenured professor in Radiation Oncology and Diagnostic Imaging with a clinical practice focused on CNS malignancies and a computational imaging lab focused on quantitative imaging and modeling to detect and characterize tumors and toxicities of treatment to enable personalized cancer treatment. Motivated by challenges observed in her own clinical and research pursuits, Dr. Chung has developed and leads institutional efforts to enable quantitative measurements for clinically impactful utilization and interpretation of data through a collaborative team science approach, including the Tumor Measurement Initiative (TMI) at MD Anderson.

Internationally, Dr. Chung leads multidisciplinary efforts to improve the generation and utilization of high quality, quantitative data to drive research and impact clinical practice, including her role as Co-Chair of the Quantitative Imaging for Assessment of Response in Oncology Committee of the International Commission on Radiation Units and Measurements (ICRU), member of the National Academies of Sciences, Engineering, and Medicine (NASEM)-appointed committee addressing Foundational Research Gaps and Future Directions for Digital Twins. She currently co-chairs the American Society of Clinical Oncology (ASCO) AI Community of Practice and served as a member of the new NIH Advisory Committee to the Director (ACD) Working Group (WG) on Artificial Intelligence (AI).

Gudrun Zahlmann, PhD is an independent consultant interested in quantitative medical imaging and the use of medical data in clinical decision support.

She has worked in Academia as well as in the imaging and pharmaceutical industry.
The importance of high-quality data as basis for any algorithmic use and the need for standardization of data generating, processing and use processes is basis for a number of her patents and formed the motivation for her engagement in International organizations like IEEE EMBS, DICOM, QIBA and EIBALL.

Transforming medical imaging into a metrology-based measuring process is the main driver of her engagement in QMIC.

Richard L. Wahl, M.D., has made numerous significant contributions to the field of quantitative imaging, particularly in nuclear medicine and molecular imaging. Some of his key contributions include:

1. Development of PET Imaging Techniques: Dr. Wahl has been instrumental in advancing positron emission tomography (PET) imaging, including the development of innovative techniques to improve image resolution and diagnostic accuracy.
2. FDG-PET: He has contributed substantially to the development and application of 18F-fluorodeoxyglucose (FDG) PET for diagnosing, staging, and monitoring the treatment of various cancers.
3. Quantitative Analysis Methods: Dr. Wahl has worked on the standardization of quantitative analysis methods in imaging, which has helped in creating reliable and reproducible quantitative metrics for assessing disease.
4. Theranostics: He has also been a pioneer in the emerging field of theranostics, which combines therapy and diagnostics, particularly using radiopharmaceuticals for both detecting and treating diseases.
5. Optimizing Imaging Protocols: He has focused on optimizing imaging protocols to enhance image quality and predictive value, often involving novel tracers and imaging systems.
6. Clinical Trials and Research: Dr. Wahl has led and participated in numerous clinical trials that have helped validate the efficacy of quantitative imaging biomarkers in managing various health conditions.

These contributions have significantly advanced the capabilities, accuracy, and application of quantitative imaging in clinical practice, ultimately improving patient care and outcomes.

Timothy J. Hall is Professor Emeritus of Medical Physics at the University of Wisconsin. Hall
has contributed to theoretical and experimental measures of acoustic scattering in simulated data, reference test materials (calibrated phantoms), and soft tissues, and developed tissue viscoelasticity imaging methods and developed phantoms for those and similar studies. His research includes metrics of observer performance in ultrasound imaging as his group continues to develop new image formation strategies based on acoustic wave propagation and tissue viscoelasticity, the development of methods for system performance evaluation, and quantitative imaging biomarker development and implementation.

Michael A. Boss is a physicist specializing in quantitative clinical imaging. Early in his career, he worked at the National Institute of Standards and Technology (NIST), where he contributed to MRI standards and metrology infrastructure to ensure imaging results are consistent and comparable across different scanners and sites.

At NIST, Dr. Boss designed a phantom to calibrate MRI scanners for quantitative diffusion imaging, allowing for rigorous quality assurance in multicenter studies, ranging from traumatic brain injury, neurodegenerative diseases, and cancer. In recognition of this work, he received the 2015 Federal Laboratory Consortium Award for Excellence in Technology Transfer and the 2016 Department of Commerce Gold Medal and Ron Brown Award for Excellence in Innovation.

In more recent years, Dr. Boss expanded his impact beyond metrology into clinical imaging and research. He has provided leadership in professional societies starting RSNA QIBA’s DWI Biomarker Committee and the ISMRM’s qMRI Study Group. As Director of the imaging core lab at the American College of Radiology, he continued efforts to push forward imaging standards and practices internationally, focusing on implementation in clinical trials. He currently serves as Associate Director, Clinical Imaging at GlaxoSmithKline, where he focuses on developing, standardizing, and implementing quantitative imaging biomarkers across MRI, CT, PET, and other modalities, focusing on their use in clinical trials and medical practice.

Richard L Ehman, MD is Professor of Radiology and is the Blanche & Richard Erlanger Endowed Professor of Medical Research at the Mayo Clinic. He has served as chair of the Radiology and Nuclear Medicine Study Section of the NIH, on the National Advisory Council of NIBIB and the Council of Councils of the NIH. He has been awarded Gold Medals by the ISMRM, the Society of Advanced Body Imaging (SABI), and the RSNA. He is a Fellow of the National Academy of Inventors and has served as president of the ISMRM, SABI, and the RSNA. He is an elected member of the National Academy of Medicine. His research program is focused on developing advanced imaging technologies. He holds more than 100 US and foreign patents for his inventions; many widely used in medical care. He and his team developed magnetic resonance elastography (MRE) a quantitative imaging technology that is now widely used in clinical practice.

Juan Carlos Ramirez-Giraldo, PhD is a medical imaging expert with more than 17 years of experience and currently serves as Senior Director of CT Collaborations at Siemens Healthineers in North America. He has co-authored over 75 peer-reviewed publications and is passionate about applying artificial intelligence to medical imaging to accelerate the adoption and implementation of imaging biomarkers. Dr. Ramirez-Giraldo also acts as a liaison for Siemens with organizations such as AdvaMed and AAPM, and at QMIC he helps strengthen connections between the consortium and its industry partners.

Dr. Daniel Sullivan is Professor Emeritus, Department of Radiology at Duke University Medical Center. He completed radiology residency and nuclear medicine fellowship in 1977 at Yale-New Haven Hospital. Over the next 20 years Dr. Sullivan held faculty appointments at Yale University Medical Center, Duke University Medical Center, and University of Pennsylvania Medical Center. He was recruited to the National Cancer Institute at NIH in 1997. From 1997 to 2007 Dr. Sullivan was Associate Director in the Division of Cancer Treatment and Diagnosis of the National Cancer Institute (NCI), and Head of the Cancer Imaging Program (CIP) at NCI. In 2007 Dr. Sullivan returned to the Department of Radiology at Duke University. His areas of clinical and research expertise are in nuclear medicine and oncologic imaging, focusing on improving the use of imaging as a biomarker in clinical trials and clinical practice.

Dr. Sullivan was Founder and Chair Emeritus of the Quantitative Imaging Biomarkers Alliance (QIBA) from 2007 to 2023. QIBA coordinated a wide range of national and international activities related to the evaluation and validation of quantitative imaging biomarkers for clinical research and practice. Subsequently, in 2024, Dr. Sullivan was one of the Founding Directors of the Quantitative Medical Imaging Coalition (QMIC).